27 October 2018

Families 4 Access and United Patients Alliance consolidated a list of questions from families and patients to send to the policy makers on Friday, in anticipation of what to expect by the 1st of November when cannabis as medicine is rescheduled.

Below, the voice of your most recurring top seven questions, in our letter to them:


Dear All, 

As you could probably imagine, we are being inundated with questions from families and patients. On behalf of The United Patients Alliance and Families 4 Access, I would like to address the most frequently asked questions coming in. We are keen to help manage expectations and help us to do so, we kindly request your help. 

Will the Interim Guidelines address these key frequently asked questions, and if not - we would seek guidance with being able to answer them. As of 1 November:

On Cannabis Based Medical Products (CBMP’s) and obtaining treatment:

How will clinicians and patients know which products are to be prescribable and on what date?

Will such prescribable products be listed as treatments for specific conditions?  

Will clinicians have details of the costs and will local CCG’s have the information required to cover these costs?

If a clinician is prepared to recommend the prescription of a CBMP, how long will the process of considering this prescription take?

Will private prescriptions be permissible, from outside the UK?

How long will the process be, from initial appointment with GP to receiving treatment?

Referral, Evidence, Prescription, Import License, Product imported to pharmacy, patient receives medication


As the interim guidelines are to be released by next week, we intend to relay these answers to our advocates.

Does this spark a question for you? Share it with us by clicking on the button below.